Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
2022 · Journal of the National Comprehensive Cancer Network · 1,599 citations
https://doi.org/10.6004/jnccn.2022.0008
H
Haeseong Park
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
309
Papers
8.4K
Citations
34
h-index
73
i10-index
Haeseong Park is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Hemoglobinopathies and Related Disorders & HER2/EGFR in Cancer Research. The author has an h-index of 34, co-authored 263 publications.
ORCID: 0000-0002-3430-8463Papers by this author
worksAntitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
2020 · Journal of Clinical Oncology · 797 citations
https://doi.org/10.1200/jco.19.02318
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
2019 · The Lancet Oncology · 227 citations
https://doi.org/10.1016/s1470-2045(19)30088-9
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
2023 · Nature Communications · 76 citations
https://doi.org/10.1038/s41467-023-36399-y
Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
2023 · Journal of Clinical Oncology · 34 citations
https://doi.org/10.1200/jco.23.00126
Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2–Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates
2023 · JCO Precision Oncology · 15 citations
https://doi.org/10.1200/po.21.00489
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat